Skip to main content
  1. Market Insights
  2. Health
  3. Pharmaceuticals

Oncology Drugs - Switzerland

Switzerland
  • In Switzerland, the projected revenue in the Oncology Drugs market is expected to reach US$1.21bn in 2024.
  • Looking ahead, it is anticipated that the revenue will experience a compound annual growth rate (CAGR 2024-2029) of 6.72%, resulting in a market volume of US$1.68bn by 2029.
  • When comparing globally, United States is forecasted to generate the highest revenue in the Oncology Drugs market, amounting to US$103.90bn in 2024.
  • Switzerland's strong pharmaceutical industry and access to cutting-edge research make it a hub for innovative oncology drug development.

Definition:
The Oncology Drugs market covers drugs to treat cancer, including chemotherapy and immunotherapy. These therapies are used for solid tumors and hematologic cancer. The medications in this market are mainly physician-administered drugs.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Bristol-Myers Squibb, Roche, Merck & Co, Novartis, Johnson & Johnson

In-Scope

  • Treatment for different types of cancer, including skin cancer, leukemia, lymphoma, and multiple myeloma
  • Chemotherapeutic agents
  • Immuno-oncology drugs
  • Oncology orphan drugs

Out-Of-Scope

  • Radiation therapy
  • Medical devices
Oncology Drugs: market data & analysis - Cover

Market Insights report

Oncology Drugs: market data & analysis

Study Details

    Revenue

    Notes: Data shown is using current exchange rates and reflects market impacts of the Russia-Ukraine war.

    Most recent update: Jun 2024

    Source: Statista Market Insights

    Notes: The chart “Comparable Estimates” shows the forecasted development of the selected market from different sources. Please see the additional information for methodology and publication date.

    Most recent update: Mar 2024

    Most recent update: Mar 2024

    Source: Statista Market Insights

    Analyst Opinion

    The Oncology Drugs market in Switzerland has been experiencing significant growth in recent years.

    Customer preferences:
    Switzerland has a high demand for innovative and effective cancer treatments. The country has a well-established healthcare system, and patients have high expectations for the quality of care they receive. Swiss patients are generally willing to pay a premium for drugs that offer better outcomes and fewer side effects.

    Trends in the market:
    In recent years, there has been a trend towards personalized medicine in the Oncology Drugs market in Switzerland. This involves tailoring treatments to the specific genetic makeup of each patient, allowing for more precise and effective treatment. Additionally, there has been an increase in the use of immunotherapy drugs, which work by stimulating the body's immune system to fight cancer cells.Local Special circumstances: Switzerland has a strong pharmaceutical industry, with many leading global companies headquartered in the country. This has led to a highly competitive market, with a wide range of drugs available to patients. Additionally, the country has a high level of research and development in the field of oncology, with many clinical trials taking place in Switzerland.

    Underlying macroeconomic factors:
    Switzerland has a high level of healthcare spending per capita, which has contributed to the growth of the Oncology Drugs market. Additionally, the country has a rapidly aging population, which has led to an increase in the incidence of cancer. The Swiss government has also taken steps to improve access to cancer treatments, including the introduction of a national cancer strategy in 2018.

    Next generation therapy

    Notes: Data shown is using current exchange rates and reflects market impacts of the Russia-Ukraine war.

    Most recent update: Sep 2024

    Source: Statista Market Insights

    Global Comparison

    Most recent update: Jun 2024

    Source: Statista Market Insights

    Methodology

    Data coverage:

    Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

    Modeling approach / Market size:

    Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

    Forecasts:

    In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

    Additional notes:

    Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

    Health

    Access more Market Insights on Health topics with our featured report

    Oncology Drugs: market data & analysis - BackgroundOncology Drugs: market data & analysis - Cover

    Key Market Indicators

    Notes: Based on data from IMF, World Bank, UN and Eurostat

    Most recent update: Sep 2024

    Source: Statista Market Insights

    Explore more high-quality data on related topic

    Cancer worldwide - Statistics & Facts

    Cancer is one of the leading causes of death worldwide, with lung cancer alone ranked the sixth leading cause of death in 2021. Cancer, also known as malignant tumors and neoplasms, is the result of interactions between personal genetic factors and external agents causing abnormal transformations of cells into tumors over time. As the global population has increased in age, the incidence of new cancer cases has also risen, contributing to a higher number of deaths each year. In 2022, nearly 10 million deaths were caused by cancer worldwide- a number which is expected to reach over 15 million by 2040.
    More data on the topic

    Contact

    Get in touch with us. We are happy to help.